Abstract
This study proposes a strategy for detecting possible dysfunction of organs such as the liver, pancreas, muscles and adipose tissues in a group of type II diabetic patients. Several in silico clinical trials are performed on a previously developed type II diabetes model. Since the pancreatic insulin secretion rate and glucose metabolic rates of different organs represent the functional behavior of the corresponding organs, calculated values of these rates are analyzed and compared with the corresponding rates calculated from a healthy subject’s model to detect possible abnormalities. These rates are calculated from estimated values of glucose and insulin concentrations inside the corresponding organs/tissues from the physiological model. Estimation of the concentrations in body organs/tissues is carried out using a sequential Monte Carlo filtering method called particle filters. The results show that the proposed strategy is capable of detecting deficiencies in hepatic and peripheral glucose disposal, hepatic glucose production and pancreatic insulin secretion. The information provided by this strategy can potentially be used to tailor patient dietary requirements and/or select appropriate medications for the patients.
This is a preview of subscription content,
to check access.




Similar content being viewed by others
Abbreviations
- G :
-
Glucose concentration (mg/dl)
- M :
-
Multiplier of metabolic rates (dimensionless)
- Q :
-
Vascular blood flow rate (dl/min)
- r :
-
Metabolic production or consumption rate (mg/min)
- T :
-
Transcapillary diffusion time constant (min)
- t :
-
Time (min)
- V :
-
Volume (dl)
- I :
-
Insulin concentration (mU/l)
- M :
-
Multiplier of metabolic rates (dimensionless)
- m :
-
Labile insulin mass (U)
- P :
-
Potentiator (dimensionless)
- Q :
-
Vascular blood flow rate (l/min)
- R :
-
Inhibitor (dimensionless)
- r :
-
Metabolic production or consumption rate (mU/min)
- S :
-
Insulin secretion rate (U/min)
- T :
-
Transcapillary diffusion time constant (min)
- t :
-
Time (min)
- V :
-
Volume (l)
- X :
-
Glucose-enhanced excitation factor (dimensionless)
- Y :
-
Intermediate variable (dimensionless)
- \(\varGamma\) :
-
Normalized glucagon concentration (dimensionless)
- M :
-
Multiplier of metabolic rates (dimensionless)
- r :
-
Metabolic production or consumption rate (dl/min)
- V :
-
Volume (dl)
- t :
-
Time (min)
- \(\varGamma\) :
-
Glucagon
- B :
-
Basal condition
- G :
-
Glucose
- I :
-
Insulin
- \(\infty\) :
-
Final steady state value
- BGU :
-
Brain glucose uptake
- GGU :
-
Gut glucose uptake
- HGP :
-
Hepatic glucose production
- HGU :
-
Hepatic glucose uptake
- KGE :
-
Kidney glucose excretion
- KIC :
-
Kidney insulin clearance
- LIC :
-
Liver insulin clearance
- \(M\varGamma C\) :
-
Metabolic glucagon clearance
- \(P\varGamma C\) :
-
Plasma glucagon clearance
- \(P\varGamma R\) :
-
Pancreatic glucagon release
- PGU :
-
Peripheral glucose uptake
- PIC :
-
Peripheral insulin clearance
- PIR :
-
Pancreatic insulin release
- RBCU :
-
Red blood cell glucose uptake
- A :
-
Hepatic artery
- B :
-
Brain
- G :
-
Gut
- H :
-
Heart and lungs
- L :
-
Liver
- P :
-
Periphery
- S :
-
Storage
- \(\infty\) :
-
Final steady-state value
- C :
-
Capillary space
- F :
-
Interstitial fluid space
References
DeFronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America, 88, 787–835. ix.
Ferrannini, E., Simonson, D. C., Katz, L. D., Reichard, G, Jr, Bevilacqua, S., Barrett, E. J., et al. (1988). The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism, 37, 79–85.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992). Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318–368.
Groop, L. C., Widen, E., & Ferrannini, E. (1993). Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: Errors of metabolism or of methods? Diabetologia, 36, 1326–1331.
Basu, A., Alzaid, A., Dinneen, S., Caumo, A., Cobelli, C., & Rizza, R. A. (1996). Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. Journal of Clinical Investigation, 97, 2351–2361.
Campbell, P. J., Mandarino, L. J., & Gerich, J. E. (1988). Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism, 37, 15–21.
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989). Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism, 38, 387–395.
Mitrakou, A., Kelley, D., Veneman, T., Jenssen, T., Pangburn, T., Reilly, J., & Gerich, J. (1990). Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes, 39, 1381–1390.
Consoli, A., Nurjhan, N., Capani, F., & Gerich, J. (1989). Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes, 38, 550–557.
Alzaid, A. A., Dinneen, S. F., Turk, D. J., Caumo, A., Cobelli, C., & Rizza, R. A. (1994). Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans. Journal of Clinical Investigation, 94, 2341–2348.
Basu, R., Schwenk, W. F., & Rizza, R. A. (2004). Both fasting glucose production and disappearance are abnormal in people with mild and severe type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism, 287, E55–E62.
Basu, R., Chandramouli, V., Dicke, B., Landau, B., & Rizza, R. (2005). Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes, 54, 1942–1948.
Basu, R., Basu, A., Johnson, C. M., Schwenk, W. F., & Rizza, R. A. (2004). Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes, 53, 2042–2050.
Basu, A., Dalla Man, C., Basu, R., Toffolo, G., Cobelli, C., & Rizza, R. A. (2009). Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care, 32, 866–872.
Iozzo, P., Hallsten, K., Oikonen, V., Virtanen, K. A., Kemppainen, J., Solin, O., et al. (2003). Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. Journal of Clinical Endocrinology and Metabolism, 88, 2055–2060.
Borra, R., Lautamaki, R., Parkkola, R., Komu, M., Sijens, P. E., Hallsten, K., et al. (2008). Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. Metabolism, 57, 1445–1451.
Pfeifer, M. A., Halter, J. B., & Porte, D, Jr. (1981). Insulin secretion in diabetes mellitus. American Journal of Medicine, 70, 579–588.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., et al. (1988). Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. New England Journal of Medicine, 318, 1231–1239.
Luzi, L., & DeFronzo, R. A. (1989). Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology, 257, E241–E246.
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999). The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation, 104, 787–794.
Leahy, J. L. (2005). Pathogenesis of type 2 diabetes mellitus. Archives of Medical Research, 36, 197–209.
Guillausseau, P. J., Meas, T., Virally, M., Laloi-Michelin, M., Medeau, V., & Kevorkian, J. P. (2008). Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes and Metabolism, 34(Suppl 2), S43–S48.
DelPrato, S., Matsuda, M., Simonson, D. C., Groop, L. C., Sheehan, P., Leonetti, F., et al. (1997). Studies on the mass action effect of glucose in NIDDM and IDDM: Evidence for glucose resistance. Diabetologia, 40, 687–697.
Nielsen, M. F., Basu, R., Wise, S., Caumo, A., Cobelli, C., & Rizza, R. A. (1998). Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes—Evidence for a concentration-dependent defect in uptake. Diabetes, 47, 1735–1747.
Lehmann, R., & Spinas, G. A. (1996). Role of physical activity in the therapy and prevention of type II diabetes mellitus. Therapeutische Umschau., 53, 925–933.
Chipkin, S. R., Klugh, S. A., & Chasan-Taber, L. (2001). Exercise and diabetes. Cardiology Clinics, 19, 489–505.
Hamdy, O., Goodyear, L. J., & Horton, E. S. (2001). Diet and exercise in type 2 diabetes mellitus. Endocrinology and Metabolism Clinics of North America, 30, 883–907.
Boden, G., Sargrad, K., Homko, C., Mozzoli, M., & Stein, T. P. (2005). Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Annals of Internal Medicine, 142, 403–411.
World Health Organization: Type II diabetes population. (2015). Retrieved from http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
Parker, R. S., Doyle, F. J., Ward, J. H., & Peppas, N. A. (2000). Robust H-infinity glucose control in diabetes using a physiological model. AIChE Journal, 46, 2537–2549.
Ramprasad, Y., Rangaiah, G. P., & Lakshminarayanan, S. (2004). Robust PID controller for blood glucose regulation in type I diabetics. Industrial and Engineering Chemistry Research, 43, 8257–8268.
Hernandez-Ordonez, M., & Campos-Delgado, D. U. (2008). An extension to the compartmental model of type 1 diabetic patients to reproduce exercise periods with glycogen depletion and replenishment. Journal of Biomechanics, 41, 744–752.
Marchetti, G., Barolo, M., Jovanovic, L., Zisser, H., & Seborg, D. E. (2008). An improved PID switching control strategy for type 1 diabetes. IEEE Transactions on Biomedical Engineering, 55, 857–865.
Farmer, T. G., Edgar, T. F., & Peppas, N. A. (2009). Effectiveness of intravenous infusion algorithms for glucose control in diabetic patients using different simulation models. Industrial and Engineering Chemistry Research, 48, 4402–4414.
Vahidi, O., Kwok, K. E., Gopaluni, R. B., & Sun, L. (2011). Developing a physiological model for type II diabetes mellitus. Biochemical Engineering Journal, 55, 7–16.
Sorensen, J. T. (1985). A physiological model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes. MIT.
Sun, L., Kwok, K. E., Gopaluni, R. B., & Vahidi, O. (2011). Pharmacokinetic-pharmacodynamic modeling of metformin for the treatment of type II diabetes mellitus. The Open Biomedical Engineering Journal, 5, 1–7.
Defronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique - method for quantifying insulin-secretion and resistance. American Journal of Physiology, 237, E214–E223.
Guyton, J. R., Foster, R. O., Soeldner, J. S., Tan, M. H., Kahn, C. B., Koncz, L., & Gleason, R. E. (1978). Model of glucose-insulin homeostasis in man that incorporates heterogeneous fast pool theory of pancreatic insulin release. Diabetes, 27, 1027–1042.
Doucet, A., Godsill, S., & Andrieu, C. (2000). On sequential Monte Carlo sampling methods for Bayesian filtering. Statistics and Computing, 10, 197–208.
Arulampalam, M. S., Maskell, S., Gordon, N., & Clapp, T. (2002). A tutorial on particle filters for online nonlinear/non-Gaussian Bayesian tracking. IEEE Transactions on Signal Processing, 50, 174–188.
Gordon, N. J., Salmond, D. J., & Smith, A. F. M. (1993). Novel-approach to nonlinear non-Gaussian Bayesian state estimation. IEEE Proceedings-F Radar and Signal Processing, 140, 107–113.
Carpenter, J., Clifford, P., & Fearnhead, P. (1999). Improved particle filter for nonlinear problems. IEEE Proceedings-Radar, Sonar and Navigation, 146, 2–7.
Crisan, D., Del Moral, P., & Lyons, T. J. (1999). Interacting particle systems approximations of the Kushner–Stratonovitch equation. Advances in Applied Probability, 31, 819–838.
Nagasaka, S., Tokuyama, K., Kusaka, I., Hayashi, H., Rokkaku, K., Nakamura, T., et al. (1999). Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stable-labeled minimal model approach. Diabetes, 48, 1054–1060.
Landahl, H. D., & Grodsky, G. M. (1982). Comparison of models of insulin release. Bulletin of Mathematical Biology, 44, 399–409.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
1.1 Appendix 1: Glucose Sub-model
The mass balance equation over each compartment in the glucose sub-model results in following equations:
The metabolic rates for the glucose sub-model are summarized below:
1.2 Appendix 2: Insulin Sub-model
The mass balance equation over the compartments in the insulin sub-model results in following equations:
The metabolic rates for the insulin sub-model are summarized below:
The pancreatic insulin release model used in the type II diabetes model has been proposed by Landahl and Grodsky [46]. The graphical representation of Landahl and Grodsky’s model is depicted in Fig. 6 in Appendix. The aim of Landahl and Grodsky’s model is to mimic the biphasic behavior of pancreatic insulin secretion in response to a glucose stimulus.
In this model, a small labile insulin compartment is assumed to exchange insulin with a large storage compartment. The rate at which insulin flows into the labile compartment is regulated by a glucose-stimulated factor, P. The rate of insulin secretion, S, is dependent on the glucose concentration, the amount of labile insulin, m, and the difference between the instantaneous level of glucose-enhanced excitation factor, X, and its inhibitor, R. This functionality provides a mathematical description of the pancreas biphasic response to a glucose stimulus. The first phase insulin release is caused by an instantaneous increase in the glucose-enhanced excitation factor (X) followed by a rapid increase in its inhibitor (R). The second phase release results from the direct dependence of the insulin secretion rate (S) on the glucose stimulus and the gradual increase in the level of the labile compartment filling factor (P).
It is assumed that the capacity of the storage compartment is large enough and remains at steady state. For a glucose concentration of zero, P is set to zero. Therefore, the steady-state mass balance equation around the storage compartment is:
where \(m_{0}\) is the labile insulin quantity at a glucose concentration of zero. The rest of the equations for the pancreas model are:
\(P_{\infty }\) and Y reflect the glucose-induced stimulation effects on the liable compartment filling factor and the insulin secretion rate, respectively.
1.3 Appendix 3: Glucagon Sub-model
The glucagon sub-model has one mass balance equation over the whole body as follows:
The metabolic rates for the glucagon sub-model are summarized below:
The model parameters are summarized in Table 3.
Rights and permissions
About this article
Cite this article
Vahidi, O., Bhushan Gopaluni, R. & Kwok, E. Detection of Abnormalities in Type II Diabetic Patients Using Particle Filters. J. Med. Biol. Eng. 35, 188–201 (2015). https://doi.org/10.1007/s40846-015-0018-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40846-015-0018-7